Welcome to our dedicated page for Clearmind Medici SEC filings (Ticker: CMND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clearmind Medicine Inc.'s SEC filings document foreign private issuer reports for a clinical-stage biotech developing non-hallucinogenic, neuroplastogen-derived psychedelic therapeutics. Form 6-K reports furnish press releases on CMND-100, MEAI-based Alcohol Use Disorder clinical development, European patent activity for PTSD compounds, and communications tied to FDA regulatory pathways.
The filings also record capital-structure matters, including securities purchase agreements, convertible promissory notes, conversions into common shares and amendments to financing capacity. Governance disclosures cover board composition, committee assignments and Nasdaq independence determinations, while incorporated registration statements on Form F-3 and Form S-8 connect current reports to the company's securities registration record.
Clearmind Medicine Inc. files a post-effective amendment registering up to 331,949 common shares for resale by selling shareholders, representing shares issuable upon exercise of January 2024 PIPE Warrants, upon effectiveness.
The combined prospectus consolidates prior registrations and updates warrant adjustments following financings and a one-for-40 reverse split. The company will not receive proceeds from resales; however, it may receive proceeds if warrants are exercised for cash. The filing discloses 2,394,806 common shares outstanding as of March 24, 2026 and lists selling holders with per-holder maximums and 4.99%/9.99% beneficial ownership limits on warrant exercises.
Clearmind Medicine Inc. reported continued progress in the third cohort of its FDA-approved Phase I/IIa trial of CMND-100, a non-hallucinogenic MEAI-based oral drug candidate for treating Alcohol Use Disorder. Patients at Yale University and Johns Hopkins University are moving through treatment with no serious adverse events reported to date, supporting the drug’s early safety and tolerability profile.
The multinational, multicenter study is designed to assess safety, tolerability, pharmacokinetics, and preliminary efficacy in moderate to severe Alcohol Use Disorder. Clearmind describes itself as a clinical-stage neuroplastogens-focused biotech with an intellectual property portfolio of nineteen patent families, including 31 granted patents.
Clearmind Medicine Inc. reported that the Intellectual Property Department in Hong Kong has published six patents covering its next-generation psychedelic-based combination therapies. These patents center on formulations that pair Palmitoylethanolamide (PEA), supplied through its partnership with NeuroThera Labs, with several classic and innovative psychedelic compounds.
The combinations include PEA with MDMA, LSD, ketamine, ibogaine, psilocybin and DMT, aiming to enhance therapeutic potential and neuroplasticity while potentially improving safety and tolerability. Clearmind describes itself as a clinical-stage neuroplastogens biotech with an intellectual property portfolio of nineteen patent families, including 31 granted patents.
L.I.A. Pure Capital Ltd. filed an amendment to a Schedule 13G reporting beneficial ownership in Clearmind Medicine Inc. The filing states 108,720 Common Shares, representing 5.0% of the class based on 2,088,806 shares outstanding as of the reporting date. The position consists of 20,470 currently held Common Shares, 93,231 shares issuable upon conversion of a convertible promissory note at a $1.25 floor conversion price, and 229,000 shares exercisable under a pre-funded warrant; exercise/conversion are subject to a 4.99% beneficial ownership blocker. The amendment is signed by Kfir Silberman as CEO on 03/16/2026.
Clearmind Medicine Inc. schedule filing: Capitalink Ltd. reports beneficial ownership of 107,943 Common Shares, representing 5.0% based on 2,088,806 shares outstanding as stated in the filing.
The filing breaks the position into (i) 32,693 Common Shares held, (ii) 93,231 Common Shares issuable upon conversion of a convertible promissory note at a $1.25 conversion price, and (iii) 229,000 Common Shares that may be acquired upon exercise of a pre-funded warrant, each within 60 days. The note and warrant include a blocker provision limiting ownership to "more than 4.99%" when combined with affiliates.
Clearmind Medicine Inc., a clinical-stage biotech company, filed a patent application in Hong Kong for a new combination therapy targeting major depressive disorder. The therapy pairs its proprietary compound 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), sourced through its partnership with NeuroThera Labs Inc.
The company highlights this MEAI-PEA approach as a non-hallucinogenic neuroplastogen-based option intended to address depression, which affects more than 332 million people worldwide, within a market expected to surpass $25 billion by 2030. Clearmind notes it currently holds nineteen patent families, including 31 granted patents, and plans to continue expanding its intellectual property portfolio.
Clearmind Medicine Inc. reported unaudited results for the three months ended January 31, 2026, showing a net loss of $3.85 million with no revenue, compared with a $1.07 million loss a year earlier. Operating expenses rose to $3.66 million, mainly from higher general and administrative and research and development costs.
Cash and cash equivalents increased to $9.26 million and working capital to $8.12 million, driven by equity issuances, warrant exercises and conversion of convertible loans into shares, which reduced total liabilities to $2.91 million. The company is funding phase I/IIa trials of its CMND‑100 psychedelic treatment for Alcohol Use Disorder, where an independent safety board approved continuation after a positive interim safety review.
Management notes negative operating cash flows of $2.08 million, an accumulated deficit of $31.73 million, and dependence on additional financing, stating that these conditions raise substantial doubt about Clearmind’s ability to continue as a going concern, even though the financial statements are prepared on a going-concern basis.
Clearmind Medicine Inc. is advancing its CMND-100 program for Alcohol Use Disorder by continuing enrollment for the third cohort of its ongoing FDA-approved Phase I/IIa clinical trial. This step follows positive topline results from the second cohort, which showed continued safety and tolerability.
The company’s Data and Safety Monitoring Board unanimously approved proceeding, allowing recruitment at leading centers including Yale University, Johns Hopkins University, and Tel Aviv Sourasky Medical Center. CMND-100 is a proprietary, non-hallucinogenic, MEAI-based oral candidate designed to treat moderate to severe Alcohol Use Disorder without requiring adjunct psychotherapy.
Clearmind Medicine Inc. filed a Form 6-K to furnish a press release announcing the publication of an international patent application under the Patent Cooperation Treaty for a novel combination therapy targeting weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD).
The therapy combines Clearmind’s proprietary compound 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA) from its collaborator NeuroThera Labs Inc. The patent publication describes the potential for a non-hallucinogenic neuroplastogen approach to address obesity and MASLD, conditions affecting large portions of the global adult population.
Clearmind notes that this therapeutic option may offer a safer, easier and more cost effective alternative compared with GLP-1 agonists, in a weight loss drugs market valued at approximately $37 billion in 2025 and forecasted to reach $226 billion by 2035. The company highlights its broader intellectual property portfolio of nineteen patent families, including 31 granted patents.
Clearmind Medicine Inc amendment reports that Nissim Daniel filed a Schedule 13G/A stating beneficial ownership in the issuer's common shares. The filing identifies the reporting person, citizenship (Israel), an address in Ramat Gan, and CUSIP 185053402, and states ownership of 5 percent or less of a class.